“Ticagrelor or Prasugrel, Doctor?” The Basis for Decision in Clinical Practice

This publication has 13 references indexed in Scilit:

• 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
  European Heart Journal, 2017
• Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
  The Lancet, 2017
• Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI
  JACC, 2016
• Optimal P2Y 12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  JACC: Cardiovascular Interventions, 2016
• Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis
  International Journal of Cardiology, 2015
• The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm
  Annals of Internal Medicine, 2015
• Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial
  Journal of Cardiovascular Translational Research, 2013
• Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention
  Circulation, 2010
• Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
  The Lancet, 2009
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
  The Lancet, 2001